Delfi Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early Detection Liquid Biopsy for Multiple Cancers
Novel liquid biopsy technology combines machine learning and low-cost cell free DNA genome-wide fragmentation profiles
BALTIMORE, Jan. 12, 2021 -- (Healthcare Sales & Marketing Network) -- Delfi Diagnostics, Inc., a pioneering developer of a new class ... Diagnostics, Oncology, Venture Capital Delfi Diagnostics
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Learning | Marketing | Pharmaceuticals | Universities & Medical Training | Venture Capital